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ABSTRACT – Purpose. A few studies have shown that normothermic hepatic ischemia-reperfusion (IR) injury 
may affect the mRNA and/or protein levels of canalicular transporters P-glycoprotein (P-gp) and multidrug 
resistance-associated protein 2 (Mrp2). However, the effects of the injury on the functions of these canalicular 
transporters with respect to the biliary excretion of drugs remain largely unknown. Therefore, the purpose of this 
study was to investigate the effects of warm hepatic IR on the hepatobiliary disposition of rhodamine 123 (RH-
123), a P-gp substrate, and its glucuronidated metabolite (RH-Glu), an Mrp2 substrate, in rats. Methods. 
Twenty four or 72 h following a 60-min partial ischemia or sham operation in rats, livers were isolated and 
perfused ex vivo with a constant concentration (~100 ng/mL) of RH-123. The concentration of RH-123 and its 
glucuronidated (RH-Glu) and deacylated (RH-110) metabolites were determined in the outlet perfusate, bile, 
and the liver tissue using HPLC, and relevant pharmacokinetic parameters were estimated.  Results. Twenty-
four-h IR caused a significant reduction in the hepatic extraction ratio of RH-123 (IR: 0.857 ± 0.078; Sham: 
0.980 ± 0.017) and the biliary recovery of the parent drug and RH-Glu by 43% and 44%, respectively. The 
reductions in the biliary recovery were associated with significant reductions in the apparent biliary clearance of 
RH-123 and RH-Glu. Mass balance data showed that the formation of the glucuronidated or deacylated 
metabolite was not significantly affected by the 24-h IR injury. In contrast to the 24-h IR, the injury did not have 
any effect on the hepatobiliary disposition of RH-123 or its metabolites following 72 h of reperfusion. 
Conclusions. It is concluded that the pharmacokinetics of drugs that are subject to biliary excretion by the 
canalicular P-gp and Mrp2 transporters may be altered shortly after hepatic IR injury.   
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________  
 
INTRODUCTION 
 
Warm hepatic ischemia-reperfusion (IR) injury is a 
serious complication of many clinical situations, 
such as hepatic resection surgery, hemorrhagic and 
septic shock, and liver transplantation (1-3). 
Numerous factors, such as the release of reactive 
oxygen species (ROS) and proinflammatory 
cytokines, have been reported to be involved in the 
pathophysiology of hepatic IR injury (4). Previous 
studies have shown that the inflammatory processes 
resulting in the release of cytokines may alter the 
expression of hepatic transporters (5, 6). Therefore, 
it is likely that the expression and function of these 
transporters are altered after the liver IR injury. 
Indeed, the limited data available in the literature 
(7-10) suggest that the mRNA and protein levels of 
the canalicular transporters P-glycoprotein (P-gp) 
and multidrug resistance-associated protein 2 
(Mrp2) may be altered by warm hepatic IR injury. 
However, the effects of the injury on the functions 
of these canalicular transporters with respect to the 
biliary excretion of drugs remain largely unknown. 
This is important because the functional changes in 
the activity of proteins do not always correlate with 
the changes in their mRNA or protein levels (11). 
Therefore, it is necessary to investigate the changes 
in the activity of liver transporters after hepatic IR 
injury. 
_________________________________________ 
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The cationic dye rhodamine 123 (RH-123) is a 
P-gp substrate, which has been used extensively as 
a marker of P-gp activity in vitro in cells, ex vivo in 
isolated organs, and in vivo in whole animals. We 
have recently (12) characterized the hepatobiliary 
disposition of RH-123 in an isolated perfused liver 
(IPRL) model and showed that the biliary excretion 
of the dye is reduced after pharmacological 
inhibition of P-gp activity (13). Additionally, it was 
shown that the biliary clearance of the 
glucuronidated metabolite of the dye (RH-Glu) is 
sensitive to the modulation of Mrp2 activity (13). 
Based on these observations, it was suggested that 
RH-123 may serve as a dual marker for the 
functions of both P-gp and Mrp2 in the IPRL model 
via simultaneous monitoring of the biliary 
clearances of the parent drug and the generated 
glucuronide metabolite, respectively (13). 
Therefore, we selected RH-123 as a marker for our 
functional studies in the present study.  
Previous studies have shown that the hepatic IR 
injury is associated with injury to remote organs, 
such as the lungs (14, 15) and kidneys (16, 17). 
This may complicate the delineation of the effects 
of hepatic IR on the canalicular efflux transporters 
after in vivo  administration of RH-123. To avoid 
these confounding effects, we chose to determine 
the hepatobiliary disposition of RH-123 and its 
metabolites ex vivo in livers isolated from the 
animals that underwent in vivo IR injury.  Earlier 
reports suggested a significant downregulation of 
mRNA (10) and protein (8) levels of Mrp2 in the 
liver as a result of hepatic IR. However, the mRNA 
(Mdr1b) (10) and protein (7) levels of P-gp were 
upregulated after the injury. Therefore, we 
hypothesized that whereas hepatic IR injury would 
increase the biliary transport of RH-123, the biliary 
excretion of its glucuronidated metabolite would be 
reduced by the injury.  
   
MATERIAL AND METHODS 
 
Chemicals and reagents 
RH-123 was obtained from MP Biomedicals 
(Solon, OH, USA). Rhodamine-110 (RH-110) and 
β-glucuronidase (TYPE -LII) were purchased from 
Sigma Chemicals Co. (St. Louis, MO, USA). For 
anesthesia, ketamine and xylazine solutions were 
purchased from Lloyd Laboratories (Shenandoah, 
IA, USA) and Fort Dodge Animal Health (Fort 
Dodge, IA, USA), respectively. Kits for 
measurement of alanine aminotransferase (ALT) 
were purchased from Teco Diagnostics (Anaheim, 
CA, USA). All other reagents were of analytical 
grade and obtained from commercial sources.  
 
Animals 
The procedures involving animals were approved 
by the Texas Tech University Health Sciences 
Center Animal Care and Use Committee and were 
consistent with the guidelines set by the National 
Institutes of Health (NIH publication #85-23, 
revised 1985). 
Adult (225-275 g), male Sprague-Dawley rats 
were purchased from Charles River Laboratories, 
Inc. (Wilmington, MA, USA). All animals were 
maintained on a 12-h light/dark cycle with free 
access to food and water before the experiments.  
 
Experimental groups and partial hepatic 
ischemia-reperfusion surgery 
A total of 28 rats underwent 1 h of partial (70%) 
ischemia (IR) or sham operation (Sham), followed 
by 24 or 72 h of in vivo reperfusion, resulting in 
four groups of Sham-24 (n=8), IR-24 (n=8), Sham-
72 (n=6), and IR-72 (n=6). 
The surgical procedures for IR were similar to 
those described before (18, 19). Briefly, after an 
overnight fast, animals were anesthetized by an 
intramuscular administration of ketamine: xylazine 
(80:10 mg/kg body weight). Partial ischemia was 
then induced by clamping those branches of the 
portal vein, hepatic artery, and bile duct that supply 
the left and median lobes of the liver, leaving the 
perfusion to the right and caudate lobes 
uninterrupted. During ischemia, temperature of the 
rat was closely monitored and maintained at 37º C 
using a combination of a heating lamp and a heating 
plate. After 60 min of partial ischemia, the clamp 
was removed to allow reperfusion. Subsequently, 5 
mL of sterile saline (37o C) was added to the 
peritoneal cavity to compensate for any volume loss 
during the surgery before closure of the abdomen. 
Sham-operated animals underwent the same 
surgical procedure without clamping. 
 
Isolation and ex vivo perfusion of livers with RH-
123 
After 24  or 72 h in vivo reperfusion, livers were 
cannulated, harvested, and perfused ex vivo for 60 
min by the method outlined by us in details earlier 
(20, 21). The perfusion was conducted in a water-
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jacketed glass perfusion system (Radnoti Glass 
Technology Inc., Monrovia, CA) using Krebs-
Henseleit bicarbonate buffer that contained 4.75 
mg/L sodium taurocholate and 1.2 g/L glucose. 
Livers were perfused at a flow rate of 30 mL/min in 
a single-pass manner with a constant concentration 
(0.1 µg/mL) of RH-123. The perfusate was 
continuously oxygenated with 95% oxygen and 5% 
carbon dioxide mixture, and the inlet perfusion 
pressure was monitored using a pressure transducer. 
The viability of the liver was confirmed by 
monitoring the macroscopic appearance of the liver, 
relatively stable bile flow rates over the entire 
period of perfusion (60 min), wet liver weight of < 
4% of total body weight at the end of perfusion, low 
transaminase (ALT) levels in the outlet perfusate 
during the perfusion period (0 and 60 min), and low 
and stable inlet pressure. 
 
Sample collection 
At the end of the 24 or 72 h of in vivo reperfusion 
period, blood was collected from the abdominal 
aorta into the heparinized syringes, and after 
centrifugation, plasma was separated and stored for 
the analysis of ALT.  
For the liver perfusion experiments, inlet 
perfusate samples were drawn at 20, 30, and 40 min 
after starting the constant infusion of RH-123. 
Additionally, outlet perfusate and bile samples were 
collected at 10 min intervals during the 60 min 
infusion of RH-123. At the end of the perfusion, 
livers were blotted dry and stored for further 
analysis. Perfusate, bile, and liver samples were 
stored at -80o C for subsequent analysis of RH-123, 
RH-110, and RH-Glu by high-performance liquid 
chromatography (HPLC). 
 
SAMPLE ANALYSIS 
 
Liver samples were homogenized in deionized 
water (1:9), and after an additional ten-fold dilution 
were used in the assay. The concentrations of RH-
123 and RH-110 in the liver homogenates, 
perfusate, and bile were analyzed by fluorescence 
HPLC both before and after treatment with -
glucuronidase, as described by us before (12). The 
concentrations of RH-Glu were then determined by 
subtracting the RH-123 concentrations in the 
unhydrolyzed samples from those in the 
corresponding hydrolyzed samples. 
Perfusate and plasma concentrations of ALT 
were measured by spectrophotometry using a 
commercially available kit. 
 
Pharmacokinetic analysis 
The areas under the perfusate concentration-time 
curve from 0 to 60 min (AUC) for RH-123, RH-
110, and RH-Glu were calculated using linear 
trapezoidal method. RH-123 inlet concentrations 
(Cin) were calculated from the average of the three 
inlet samples drawn at 20, 30, and 40 min of 
perfusion. The time-averaged hepatic availability of 
RH-123 during the 60-min perfusion period (F) was 
estimated using the following equation: 
 
F  Xout
Xin
  (1) 
 
where Xout and Xin are the amount of RH-123 
recovered in the perfusate from zero to 60 min and 
the total dose of RH-123 administered during the 
same period, respectively. Xout was estimated by 
multiplying the perfusate AUC of RH-123 by the 
perfusate flow (Q), which was 30 mL/min, and Xin 
was estimated by multiplying the Cin by the Q and 
duration of the perfusion (60 min). The time-
averaged hepatic extraction ratio (E) and hepatic 
clearance (CLh) of RH-123 were then estimated 
using the following equations: 
 
E 1F   (2) 
CLh QE   (3) 
 
Biliary excretion rates of RH-123 and RH-Glu at 
any given time interval were determined by 
dividing the total amount of the drug or metabolite 
excreted into the bile during that interval by the 
length of the collection interval. The apparent 
biliary clearance (CLbile,app) of RH-123 or its 
generated metabolite RH-Glu were estimated by 
dividing the total amount of the drug or the 
metabolite excreted into the bile during the 60 min 
of perfusion by its respective perfusate AUC during 
the same period. Because of continuous 
accumulation and sequestration of RH-123 in the 
liver tissue during the constant infusion of RH-123 
in IPRLs despite pseudo-steady state perfusate 
concentrations, the CLbile,app of RH-123 is expected 
to increase with an increase in the length of 
perfusion (12). Therefore, another parameter, 
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termed biliary excretion index (BEI), was also 
calculated for RH-123 as shown in the following 
equation: 
 
BEI  (%)  Dbile
Dliver
100  (4) 
 
where Dbile and Dliver are the amounts of RH-123 
recovered in the bile during the perfusion period 
and that recovered in the liver at the end of 
perfusion, respectively. This parameter is similar in 
concept to the BEI estimated in sandwich-cultured 
rat hepatocytes (22).  In contrast to CLbile,app, which 
normalizes the amount of RH-123 excreted in the 
bile by the extent of drug exposure in the perfusate, 
BEI normalizes the biliary excretion of the drug by 
the extent of its liver accumulation. Therefore, it is 
not expected to be dependent on the length of 
constant infusion of the drug in IPRLs. 
 
STATISTICAL ANALYSIS 
 
The effects of IR and time of reperfusion on 
different kinetic parameters were tested using two-
way ANOVA followed by Bonferroni’s post-hoc 
analysis of the means. Also, two-way ANOVA with 
repeated measures followed by Bonferroni’s post-
hoc was used to compare the biliary excretion rates 
at different time points across the four treatment 
groups. In all the cases, p<0.05 was considered 
significant. All data are presented as mean ± SD. 
 
RESULTS 
 
The plasma concentrations of ALT, as a marker of 
liver damage after IR, are shown in Figure 1. 
Whereas the plasma concentrations of ALT in the 
IR group were significantly (p<0.001) higher than 
those in the Sham group 24 h after the in vivo 
reperfusion, similar concentrations of ALT were 
found in the IR and Sham groups at 72 h post-
reperfusion (Figure 1). 
The outlet perfusate concentration-time profiles 
and associated pharmacokinetic parameters of RH-
123 and its metabolites are depicted in Figure 2 and 
Table 1, respectively. Except for the IR-24 group, 
the pseudo-steady-state outlet perfusate 
concentrations of RH-123 in all different groups 
were similarly low (3-5 ng/mL) (Fig 2A), resulting 
in extensive extraction ratios of 0.972-0.980 and 
high CLh values close to the perfusion flow rate of 
30 mL/min (Table 1). 
 
Figure 1. The plasma concentrations of alanine 
aminotransferase (ALT) following 24 or 72 h of 
reperfusion in rats subjected to 60 min of partial 
ischemia (IR) or sham operation (Sham). The columns 
and bars represent the mean and SD values, respectively. 
*** p<0.001, significantly different from the respective 
Sham group based on two-way ANOVA, followed by 
Bonferroni’s post-hoc analysis. 
 
 
However, the outlet concentrations (Figure 2A) and 
AUC values (Table 1) for the IR-24 group were 
much higher (p<0.001) than those of the Sham-24 
group. In addition, the extraction ratio and CLh of 
RH-123 were significantly (p<0.001) lower in this 
group (Table 1). Whereas the outlet concentrations 
and AUC values of the deacylated metabolite (RH-
110) were similar in all of the four groups (Figure 
2B and Table 1), those of RH-Glu were 
significantly (p<0.01) increased in the IR-24 group 
(Figure 2C and Table 1). 
The biliary excretion rate-time profiles (A) and 
fraction of the dose recovered in the bile  (B) are 
depicted in Figures 3 and 4 for the parent drug RH-
123 and the formed RH-Glu metabolite, 
respectively.  The biliary excretion rates of RH-123 
and RH-Glu in the IR-24 group were significantly 
(p<0.05 or < 0.01) lower during some intervals, 
when compared with the rates at the corresponding 
times in the control group (Sham-24) (Figures 3A 
and 4A). Likewise, the biliary recoveries of RH-123 
and RH-Glu in the IR-24 rats were reduced 
(p<0.05) by 43% (Figure 3B) and 44% (Figure 4B), 
respectively. In contrast, both the biliary excretion 
rates and recoveries of RH-123 and RH-Glu in the 
IR-72 group were not different from those in the 
Sham-72 group (Figures 3 and 4).
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Figure 2. The outlet perfusate concentration-time 
profiles of RH-123 (A), RH-110 (B), and RH-Glu (C) in 
isolated livers perfused with a constant inlet 
concentration of 100 ng/mL of RH-123 for 60 min. 
Livers were collected from rats subjected to 1 h of partial 
hepatic ischemia (IR) or sham operation (Sham), 
followed by 24 or 72 h of in vivo reperfusion. Mean 
values are shown without SD bars for clarity. 
 
 
Figure 3. The biliary excretion rate-time profiles (A) and 
cumulative biliary excretion (B) of RH-123 in isolated 
livers perfused with a constant inlet concentration of 100 
ng/mL of RH-123 for 60 min. Livers were collected from 
rats subjected to 1 h of partial hepatic ischemia (IR) or 
sham operation (Sham), followed by 24 or 72 h of in vivo 
reperfusion. The symbols or columns represent the mean 
values and bars represent the SD values. * p<0.05 and ** 
p<0.01, significantly different from the respective Sham 
group based on repeated measure (A) or regular (B) two-
way ANOVA, followed by Bonferroni’s post-hoc 
analysis. 
Table 1. Perfusate Pharmacokinetic Parameters of RH-123 and Its Main Metabolites RH-110 and RH-Glu in IPRL 
Preparations 
Treatment AUC (ng.min/mL)  RH-123 RH-123 RH-110 RH-Glu  E CLh (mL/min) 
Sham-24 112 ± 95 328 ± 216 44.6 ± 37.5  0.980 ± 0.017 29.4 ± 0.5 
IR-24 801 ± 445*** 240 ± 50 89.6 ± 21.7**  0.857 ± 0.078*** 25.7 ± 2.3*** 
Sham-72 117 ± 49 308 ± 39 57.2 ± 17.9  0.979 ± 0.009 29.4 ± 0.3 
IR-72 160 ± 55 291 ± 16 37.5 ± 10.9  0.972 ± 0.009 29.1 ± 0.3 
Livers were collected from rats subjected to 1 h of partial hepatic ischemia (IR) or sham operation (Sham), followed by 
24 or 72 h of in vivo reperfusion and perfused ex vivo with a constant concentration (100 ng/mL) of RH-123 for 60 
min.Data are presented as mean ± SD. ** p<0.01 and *** p<0.001, significantly different from the corresponding Sham 
group (two-way ANOVA followed by Bonferroni’s post-hoc analysis). 
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Figure 4. The biliary excretion rate-time profiles (A) and 
cumulative biliary excretion (B) of RH-Glu in isolated 
livers perfused with a constant inlet concentration of 100 
ng/mL of RH-123 for 60 min. Livers were collected from 
rats subjected to 1 h of partial hepatic ischemia (IR) or 
sham operation (Sham), followed by 24 or 72 h of in vivo 
reperfusion. The symbols or columns represent the mean 
values and bars represent the SD values. * p<0.05, 
significantly different from the respective Sham group 
based on repeated measure (A) or regular (B) two-way 
ANOVA, followed by Bonferroni’s post-hoc analysis. 
 
 
The apparent biliary clearance (A) and BEI (B) 
of RH-123 and CLbile,app of RH-Glu (C) are 
presented in Figure 5. The BEI values could not be 
estimated for RH-Glu because, in agreement with a 
previous report (12), no RH-Glu was detected in the 
liver. Both CLbile,app (Figure 5A) and BEI (Figure 
5B) values of RH-123 in the IR-24 group were 
substantially lower than the corresponding values in 
the Sham-24 group. However, the extent of 
reduction in the CLbile,app value (92%, p<0.001) was 
more than that observed in the BEI value (50%). 
The CLbile,app value of  RH-Glu was also reduced 
(p<0.01) by 83% as a result of IR injury in the 24 
h-reperfusion group (Figure 5C). Similar to other 
kinetic parameters, no differences were observed 
between the IR-72 and Sham-72 groups in their 
CLbile,app and BEI values (Figure 5). 
 
 
Figure 5. The apparent biliary clearance (A) and biliary 
excretion index (B) of RH-123 and apparent biliary 
clearance of RH-Glu (C) in isolated livers perfused with 
a constant inlet concentration of 100 ng/mL of RH-123 
for 60 min. Livers were collected from rats subjected to 1 
h of partial hepatic ischemia (IR) or sham operation 
(Sham), followed by 24 or 72 h of in vivo reperfusion. 
The columns and bars represent the mean and SD values, 
respectively. ** p<0.01 and *** p<0.001, significantly 
different from the respective Sham group based on two-
way ANOVA, followed by Bonferroni’s post-hoc 
analysis. 
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The mass balance data for RH-123 (A), RH-Glu 
(B), RH-110 (C), and total drug/metabolites (D) are 
presented in Figure 6. The major moiety recovered 
was the parent drug (Figure 3A), which was present 
in the perfusate, bile, and the liver tissue, with the 
highest recovery (26-35% of the dose) in the liver 
tissue. RH-Glu was present in the perfusate and bile 
only, and RH-110 was present in the perfusate and 
liver tissue only. Neither IR-24 nor IR-72 had any 
significant effect on the overall recovery of RH-123 
(Figure 6A), RH-Glu (Figure 6B), or RH-110 
(Figure 6C) or the total mass balance (Figure 6D). 
 
 
Figure 6. The mass balance data for RH-123 (A), RH-
Glu (B), RH-110 (C), and total drug/metabolites (D) in 
isolated livers perfused with a constant inlet 
concentration of 100 ng/mL of RH-123 for 60 min. 
Livers were collected from rats subjected to 1 h of partial 
hepatic ischemia (IR) or sham operation (Sham), 
followed by 24 or 72 h of in vivo reperfusion. The 
columns and bars represent the mean and SD values, 
respectively. 
 
 
The bile flow rates for individual intervals and 
the average bile flow rates during the entire 60 min 
perfusion of livers are presented in Figure 7. 
Whereas the bile flow rates at the later intervals 
were significantly (p<0.05) lower for the IR-24 
group, relative to the values for the Sham-24 group 
(Figure 7A), there was no difference in the flow 
rates between the 72 h reperfusion groups (Figure 
7B). In agreement with the individual interval data 
(Figures 7A and B), the average flow rate for the 
IR-24 group was 23% lower (p<0.05) than that in 
the Sham-24 group (Figure 7C). 
 
DISCUSSION 
 
Recent reports (7, 8, 10) have shown that partial 
liver IR injury significantly alters the gene 
expression of Mrp2 and Mdr1b (P-gp) in the liver 
of rats. Because these two transporters play a major 
role in the biliary excretion of a number of drugs, 
the pharmacokinetics of these drugs may be 
significantly altered after the IR injury. In the 
present study, we used an IPRL model to 
investigate the effect of warm hepatic IR injury on 
the hepatobiliary disposition of RH-123, which is a 
dual marker of P-gp and Mrp2 function. Warm 
hepatic IR injury significantly altered the 
hepatobiliary disposition of RH-123, which is a P-
gp marker, and its glucuronidated metabolite, which 
is excreted into the bile by Mrp2 (Figures 3-5). 
Both biliary excretion and biliary clearance (or 
BEI) of RH-123 and RH-Glu were significantly 
reduced after hepatic ischemia followed by 24 h of 
reperfusion. However, both of these parameters 
returned to normal levels after 72 h of reperfusion 
(Figures 3-5). These data suggest substantial 
decreases in the functional activity of both P-gp and 
Mrp2 transporters 24 h following the IR injury.   
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Figure 7. The 10-min interval bile flow rates for the 24 
(A) and 72 (B) h reperfusion groups and the average bile 
flow rates during the entire 60 min of ex vivo perfusion 
(C) in isolated livers. Livers were collected from rats 
subjected to 1 h of partial hepatic ischemia (IR) or sham 
operation (Sham), followed by 24 or 72 h of in vivo 
reperfusion. The columns and bars represent the mean 
and SD values, respectively. * p<0.05, significantly 
different from the respective Sham group based on 
repeated measure (A and B) or regular (C) two-way 
ANOVA, followed by Bonferroni’s post-hoc analysis. 
The decrease in the biliary excretion (Figure 4) and 
CLbile,app (Figure 5C) of the generated RH-Glu, 
observed in our studies, is in agreement with the 
reported (8-10, 23) downregulation of the mRNA 
and protein levels of this transporter as a result of 
hepatic IR injury. 
In a partial IR model in rats identical to ours, 
Tanaka et al. (8, 10) showed that the hepatic IR 
injury caused a significant reduction in the Mrp2 
mRNA in the liver tissue following 60 min of 
ischemia and 24 h of reperfusion. However, the 
mRNA levels returned to normal values after 48 h 
of reperfusion. The decrease in the mRNA levels at 
24 h (8, 10) was accompanied by 88 and 80% 
reductions in the Mrp2 protein expression after 24 
and 48 h of reperfusion, respectively (8). However, 
the downregulation of the protein expression was 
more extensive than that of mRNA, suggesting 
additional post-transcriptional downregulation of 
Mrp2 by IR (8). Our observation that the hepatic IR 
decreases the CLbile,app of RH-Glu, a substrate of 
Mrp2, by 83% after 24 h of reperfusion (Figure 5 
C) is in close agreement with the findings of 
Tanaka et al. Furthermore, our data suggest that this 
effect is abolished 72 h following the reperfusion 
(Figure 5C). 
In addition to a reduced transport function for 
Mrp2, our studies also revealed a substantial IR-
induced reduction in the activity of P-gp, as 
demonstrated by 92 and 50% reductions in the 
CLbile,app (Figure 5A) and BEI (Figure 5B) of RH-
123, respectively. The reduction in the transport 
activity of P-gp, however, does not correlate with 
the limited data available on the effects of hepatic 
IR on the Mdr1b mRNA (10) or P-gp protein 
expression (7) reported before. Significant increases 
(≥ 50%) in the Mdr1b mRNA was reported 6, 24, 
and 48 h following reperfusion of rat livers (10). 
Additionally, we are aware of one study (7) that 
showed a modest (~20%), but statistically 
significant, increase in the P-gp protein expression 
in the liver of rats 12 h following reperfusion. The 
lack of correlation between the P-gp expression and 
functional activity, which has also been reported by 
others (11, 24), may be due to several reasons. One 
likely mechanism is that changes in the energy 
status of the liver may be responsible for the 
decreased activity of P-gp, an ATP binding cassette 
transporter protein. Liver ATP concentrations, 
which substantially decrease during the ischemic 
period, gradually recover during the reperfusion of 
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the liver (25, 26). Our attempts to accurately 
measure the ATP concentrations in our IPRLs at the 
end of the perfusion were unsuccessful because of 
the extremely rapid and variable degradation of 
ATP during the period between the end of perfusion 
and preparation of the livers for the storage at 
-80oC. However, using an IR model identical to 
ours (60 min of partial ischemia in rats), Ofluoglu et 
al. (27) reported that after 24 h of reperfusion, the 
hepatic concentrations of ATP were ~30% lower 
than that of sham-operated animals. Therefore, a 
decrease in the liver ATP concentrations might 
have superseded the modest increase reported (7) in 
the protein levels of P-gp, explaining the lower P-
gp activity observed  in our IR-24 group. 
Another possible reason for the apparent lack of 
correlation between the P-gp protein and function 
after hepatic IR may be related to the intracellular 
trafficking of P-gp after the injury. The reported (7) 
IR-induced increase in the P-gp expression was 
based on Western blot analysis, which is a measure 
of total tissue P-gp. However, it is possible that P-
gp is retrieved from the bile canalicular membranes 
into intrahepatic sites in the IR-24 livers. Indeed, it 
has been reported (28, 29) that various factors, such 
as the concentrations of cAMP, taurocholate, Ca++, 
or ATP, which may potentially be altered after IR 
injury, may affect the distribution of P-gp between 
the canalicular membranes and intracellular sites at 
the canalicular membrane. 
It has been reported (30) that the uptake of RH-
123 in sandwich cultured rat hepatocytes consists of 
both linear and saturable components, with Oatp1a4 
as the likely carrier for the latter. Therefore, it may 
be argued that an IR-induced decrease in the uptake 
of RH-123 into the liver might have led to a 
decrease in its biliary excretion. The possibility of 
an IR effect on the influx transporters cannot be 
ruled out based on our data. However, such an 
effect, if indeed exists, cannot by itself explain our 
biliary excretion data for RH-123 (Figures 5A and 
B).  Whereas a possible reduction in the uptake of 
RH-123 may cause a reduction in CLbile,app (Figure 
5A), it cannot explain the reduction observed in the 
BEI value (Figure 5B). This is because CLbile,app is 
estimated by dividing the rate (or amount) of the 
drug excreted into the bile by its corresponding 
perfusate concentration (or AUC). Therefore, a 
reduction in the uptake, causing an increase in the 
perfusate exposure to drug, will be reflected as a 
reduction in CLbile,app. However, BEI, which relates 
the biliary excretion of the drug to its accumulation 
in the liver (equation 4), instead of the perfusate, is 
only a reflection of the efflux (from the liver to bile) 
and not the uptake (from the perfusate to the liver) 
of the drug. Indeed, the much higher magnitude of 
reduction (92%) in CLbile,app (Figure 5A), compared 
with the 50% reduction in BEI (Figure 5B), as a 
results of IR-24, might have been due to additional 
effects of IR-24 on the uptake of RH-123, which 
could only be reflected in CLbile,app and not BEI.  
Our suggestion that IR-24 decreases the 
transport function of Mrp2 is based on the IR-
induced reduction in the CLbile,app of RH-Glu 
generated after the administration of RH-123. 
Therefore, it may be argued that the biliary 
excretion of RH-Glu might have been influenced by 
potential changes in the formation of the metabolite 
as a result of IR. However, the fact that the mass 
balance data for the conjugated metabolite was not 
affected by IR (Figure 6B) suggests that IR does not 
affect the glucuronidation of RH-123. Nevertheless, 
future studies using direct administration of Mrp2 
substrates are needed to confirm the results 
presented here using the formed metabolite RH-
Glu. 
In addition to the no change in the extent of 
glucuronidation of RH-123 (Figure 5B), mass 
balance data also suggest that the hepatic IR injury 
does not have any effect on the formation of RH-
110 in our model at 24 or 72 h after the reperfusion 
(Figure 6C). Recently (18), we showed a significant 
reduction in the cytochrome P450 reductase and 
cytochrome P450 2E1-mediated metabolism of 
chlorzoxazone 3 h following reperfusion of the 
ischemic livers. However, the effect of IR on the 
P450-mediated metabolism was absent at 24 h 
following reperfusion. The lack of the effect of IR-
24 or IR-72 on the deacylation of RH-123 to RH-
110, observed here, is similar to the absence of the 
effects of IR on cytochrome P450 reductase and 
cytochrome P450 2E1 metabolism of 
chlorzoxazone at 24 h following reperfusion. 
In conclusion, warm hepatic IR injury reduces 
the activities of both P-gp and Mrp2 in the rat liver 
24 h after reperfusion of livers subjected to 60 min 
of partial ischemia. However, the functions of these 
transporters return to normal levels 72 h after 
reperfusion. If extrapolated to humans, these 
findings may have clinical ramifications for Mrp2 
and P-gp substrate drugs that are administered 
during the first 24 h after the ischemic insult to the 
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liver. Further studies, including in vivo and 
mechanistic experiments, are needed to determine 
the effects of liver IR injury on the extent of 
alterations in the overall pharmacokinetics and 
pharmacodynamics of drugs whose elimination is 
dependent on their excretion into the bile. 
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